Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Loreto

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Neurobiology of Disease|November 20, 2019
Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degenerationAndrea Loreto, Ciaran S Hill, Victoria L Hewitt, et al.
Current Biology : CB|March 7, 2017
NMN Deamidase Delays Wallerian Degeneration and Rescues Axonal Defects Caused by NMNAT2 Deficiency In VivoMichele Di Stefano, Andrea Loreto, Giuseppe Orsomando, et al.
Elife|December 8, 2022
The NAD<sup>+</sup> precursor NMN activates dSarm to trigger axon degeneration in <i>Drosophila</i>Arnau Llobet Rosell, Maria Paglione, Jonathan Gilley, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2022
Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domainHannah C Feldman, Elisa Merlini, Carlos Guijas, et al.
Acta Neuropathologica Communications|October 30, 2019
Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine lossMatthew A White, Ziqiang Lin, Eugene Kim, et al.
Nature Communications|September 17, 2024
Author Correction: NMNAT2 is a druggable target to drive neuronal NAD productionJames R Tribble, Melissa Jöe, Carmine Varricchio, et al.
Elife|December 6, 2021
Neurotoxin-mediated potent activation of the axon degeneration regulator SARM1Andrea Loreto, Carlo Angeletti, Weixi Gu, et al.
Nature Communications|July 24, 2024
NMNAT2 is a druggable target to drive neuronal NAD productionJames R Tribble, Melissa Jöe, Carmine Varricchio, et al.
Neurobiology of Disease|June 5, 2025
SARM1 activation induces reversible mitochondrial dysfunction and can be prevented in human neurons by antisense oligonucleotidesAndrea Loreto, Kaitlyn M L Cramb, Lucy A McDermott, et al.
Plos One|July 19, 2012
Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetesGiovanni Di Pasquale, Ilaria Dicembrini, Laura Raimondi, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Neurobiology of Disease|November 20, 2019
Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degenerationAndrea Loreto, Ciaran S Hill, Victoria L Hewitt, et al.
Current Biology : CB|March 7, 2017
NMN Deamidase Delays Wallerian Degeneration and Rescues Axonal Defects Caused by NMNAT2 Deficiency In VivoMichele Di Stefano, Andrea Loreto, Giuseppe Orsomando, et al.
Elife|December 8, 2022
The NAD<sup>+</sup> precursor NMN activates dSarm to trigger axon degeneration in <i>Drosophila</i>Arnau Llobet Rosell, Maria Paglione, Jonathan Gilley, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2022
Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domainHannah C Feldman, Elisa Merlini, Carlos Guijas, et al.
Acta Neuropathologica Communications|October 30, 2019
Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine lossMatthew A White, Ziqiang Lin, Eugene Kim, et al.
Nature Communications|September 17, 2024
Author Correction: NMNAT2 is a druggable target to drive neuronal NAD productionJames R Tribble, Melissa Jöe, Carmine Varricchio, et al.
Elife|December 6, 2021
Neurotoxin-mediated potent activation of the axon degeneration regulator SARM1Andrea Loreto, Carlo Angeletti, Weixi Gu, et al.
Nature Communications|July 24, 2024
NMNAT2 is a druggable target to drive neuronal NAD productionJames R Tribble, Melissa Jöe, Carmine Varricchio, et al.
Neurobiology of Disease|June 5, 2025
SARM1 activation induces reversible mitochondrial dysfunction and can be prevented in human neurons by antisense oligonucleotidesAndrea Loreto, Kaitlyn M L Cramb, Lucy A McDermott, et al.
Plos One|July 19, 2012
Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetesGiovanni Di Pasquale, Ilaria Dicembrini, Laura Raimondi, et al.
Pageof 4